MFMirasol Forcadela

Mirasol Forcadela

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mirasol Forcadela has a total of 147 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Australian consensus recommendations for the management of increased meningococcal infection risk in adults with neurological diseases treated with complement inhibitors

    by Katherine A. Buzzard, Michael Barnett, Heidi Beadnall, Mirasol Forcadela, Lesley‐Ann Hall, Victoria G. Hall, Todd Hardy, Danny Hsu, Paul Kinsella, Mastura Monif, et al.

    Complement inhibitor therapy carries a risk of serious infections, including meningococcal disease. Here we provide evidence‐based recommendations and expert consensus for immunisation and prophylactic treatment of patients receiving, or planning to receive, complement inhibitors for neurological conditions in the Australian setting. The primary aim of these consensus recommendations is to minimise the risk of vaccine‐preventable infections and to outline alternative infection‐prevention strategies where vaccination is problematic. We address disease‐specific risks and propose timing considerations, including a pragmatic approach to clinical implementation.


  • Characterising executive functioning in the chronic phase of autoimmune encephalitis: A study by the Australian autoimmune encephalitis consortium

    by Katherine Y. Ko, Nabil Seery, Sarah Griffith, Christina Kazzi, Robb Wesselingh, Tiffany Rushen, Tracie H. Tan, Hannah Ford, Catherine Meade, Marie F. O'SHea, et al.

  • Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

    by Smathorn Thakolwiboon, Vyanka Redenbaugh, Bo Chen, Sage Hewitt, Shailee Shah, Itay Lotan, Michael Levy, Mirasol Forcadela, Saif Huda, Julie Pique, et al.

    Data on the plasma exchange (PLEX) in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are limited. Herein, we evaluate outcomes after PLEX in MOGAD. This international multicenter retrospective cohort study included patients from 18 tertiary care centers in 6 countries. Inclusion criteria included fulfillment of the 2023 International MOGAD panel criteria, receipt of at least 3 sessions of PLEX, and follow-up of ≥3 months after PLEX. Patients with coexisting neuroinflammatory disorders were excluded. We assessed the frequency of complete recovery (CR), clinically significant improvement (CSI), visual acuity (VA), and Expanded Disability Status Scale (EDSS). Logistic regression analyses were performed to identify predictors of CR and CSI. Of 234 patients, 135 (58%) were female. The median (interquartile range [IQR]) age at attack was 34 (IQR 22-49) years, and 42 (17%) were children. In 165 of 243 (68%), the attack treated with PLEX was the first attack. Attack phenotypes included 161 optic neuritis (235 eyes), 77 myelitis, 24 acute disseminated encephalomyelitis, 15 brainstem/cerebellar, 3 cerebral-cortical encephalitis attack, and 1 cerebral polyfocal deficit-36 with >1 core phenotypes. A total of 239 (99%) attacks were also treated with corticosteroids and 32 (13%) with IV immunoglobulins. VA in optic neuritis improved from 20/400 (20/70-hand motion) to 20/20 (20/20-20/30), p < 0.001, and EDSS decreased from a median of 4.0 (3.0-6.5) to 1.0 (0.0-2.5), p < 0.001. Of 229 attacks without subsequent attacks within 3 months, 100 (44%) achieved CR and 213 (93%) CSI. The probability of CR was decreased with advanced age (adjusted odd ratio [95% CI] 0.97 [0.96-0.99] per year), higher EDSS worsening from baseline (0.66 [0.54-0.81] per 0.5 increment) and delayed PLEX (0.98 [0.96-0.99] per day). Advanced age (0.97 [0.96-0.99] per year) and delayed PLEX (0.95 [0.94-0.96] per day) decreased the probability of CSI. We observed favorable outcomes after PLEX in MOGAD attacks. However, advanced age and delayed initiation of PLEX were associated with a reduced probability of improvement. The absence of a control group limits our ability to differentiate PLEX effects from spontaneous recovery, prior corticosteroid response, or long-term immunotherapy. Future prospective studies are needed to assess the impact of PLEX on improvement. This study provides Class IV evidence that PLEX is associated with favorable clinical outcomes in patients with MOGAD.


  • Open Access

    Acute and Long-Term Immune-Treatment Strategies in Anti-LGI1 Antibody–Mediated Encephalitis

    by Nabil Seery, Robb Wesselingh, Paul Beech, Laurie M. McLaughlin, Tiffany Rushen, Amy J. Halliday, Liora ter Horst, Sarah P. Griffith, Mirasol Forcadela, Tracie H. Tan, et al.

    Few studies have evaluated acute immunotherapy and relapse prevention strategies in patients with anti-leucine-rich glioma-inactivated 1 (LGI1) antibody (Ab)-mediated encephalitis. The objective of this study was to analyze the outcomes of acute and long-term immunotherapy strategies in this population. We undertook a multicenter cohort study of 55 patients with anti-LGI1 Ab-mediated encephalitis, either recruited prospectively or identified retrospectively from 10 Australian hospitals as part of the Australian Autoimmune Encephalitis Consortium. Clinical data were collected, including treatment durations of all relevant immunotherapies. Clinical outcomes that we examined included (1) time to first clinical relapse, (2) improvement on modified Rankin Scale (mRS), and (3) favorable binary composite clinical-functional outcome at 12 months. A favorable outcome was defined as fulfilling all three of mRS less than 3, a score of 1 or less in the memory dysfunction component of the Clinical Assessment Scale in Autoimmune Encephalitis, and absence of drug-resistant epilepsy. Rituximab, adjusted for concomitant use of other immunotherapies, was associated with increased time to first relapse (hazard ratio 0.10; 95% CI 0.001-0.85; p = 0.03). Intravenous pulsed methylprednisolone was associated with an improvement in mRS (OR 4.48; 95% CI 1.03-21.3; p = 0.048) and a favorable composite clinical-functional outcome (OR 4.96; 95% CI 1.07-27.2; p = 0.049) at 12 months. Rituximab may be effective at preventing relapses in patients with anti-LGI1 Ab-mediated encephalitis. Acute methylprednisolone treatment may be associated with favorable outcomes at 12 months. This study provides Class IV evidence that for patients with anti-LGI1 Ab-mediated encephalitis, rituximab prevents relapses and acute methylprednisolone is associated with favorable outcomes at 12 months.


  • Open Access

    Rituximab Use for Relapse Prevention in Anti-NMDAR Antibody-Mediated Encephalitis

    by Nabil Seery, Robb Wesselingh, Paul Beech, Laurie McLaughlin, Tiffany Rushen, Amy J. Halliday, Liora Ter Horst, Sarah P. Griffith, Mirasol Forcadela, Tracie H. Tan, et al.

    Rituximab is an anti-CD20 monoclonal antibody used in patients with anti-NMDAR antibody (Ab)-mediated encephalitis as both an acute escalation therapy and a longer term relapse risk-reduction treatment. The potential long-term benefit of a single course administered during the acute disease phase on future relapse risk is uncertain. Moreover, the optimal dosing duration to reduce relapse risk is unknown. The aim of this study was to evaluate the effect of a single course of rituximab on relapse incidence. We also studied the duration of effect of a course of rituximab in adult patients with anti-NMDAR Ab-mediated encephalitis. We recruited 67 patients with anti-NMDAR Ab-mediated encephalitis from 10 Australian hospitals. Rituximab exposure was quantified as a time-varying covariate in Cox proportional hazard models. A single course of rituximab was associated with longer time to first relapse (hazard ratio [HR] 0.11, 95% CI 0.02-0.70, p = 0.02). For patients in whom redosing is considered, rituximab was associated with longer time to first relapse at 6 months after the last infusion, after adjusting for concurrent immunotherapies and the presence of ovarian teratoma at disease onset (HR 0.05, 95% CI 0.00-0.48, p = 0.005). The treatment effect did not persist out to 12 months after a given course (HR 0.60, 95% CI 0.15-2.44, p = 0.47). A single course of rituximab reduces the risk of relapse of anti-NMDAR antibody-mediated encephalitis. In select patients for whom redosing of rituximab is considered, administration at 6 months delays relapses. This study provides Class IV evidence that rituximab delays relapses in patients with anti-NMDAR antibody-mediated encephalitis.


  • Cephalgic syndromes following optic neuritis: a case series

    by Forcadela Mirasol, Rocchi Chiara, Hamid Shahd, Huda Saif

    Introduction Neuropathic pain is common after spinal cord inflammation and trigeminal neuralgia may be expected with brainstem inflammation, particularly in multiple sclerosis. Interestingly we have observed ipsilateral facial pain following optic neuritis (ON) in several patients. Aim To describe 5 patients with ipsilateral facial pain following ON Results Five patients (60% female) presented with ON which was bilateral in 1 case. MOG-IgG was positive in 3/5 cases and visual acuity at nadir was: 6/18, finger-counting, and hand movements in 3 patients. Four patients had IV methylprednisolone of which one also had plasma exchange. At 3 months, 2 showed no improvement, two moderate improvement, and one full recovery. Brainstem involvement was observed in 1 patient. All developed sharp ipsilateral V1 facial pain, 1 patient’s pain extended into V2. One patient fulfilled ICHD-3 criteria for short unilateral neuralgiform headaches with conjunctival tearing (SUNCT). Variable responses to greater occipital nerve blocks, Amitriptyline, and Lamotrigine were observed. Conclusion Ipsilateral facial pain may complicate optic neuritis independent of brainstem involvement. We hypothesise a mechanism involving sensitisation of trigeminal afferents and the trigeminal autonomic reflex pathway. Increased recognition of this complication may help to identify an optimal treatment approach.

  • 5-year experience of cyclophosphamide rescue therapy in non-MS CNS inflammation from a national referral centre

    by Forcadela Mirasol, Rocchi Chiara, Hamid Shahd, Huda Saif

    Introduction Non-multiple sclerosis CNS inflammation encompasses conditions including neuromyelitis optica spectrum disorder (NMOSD), MOG-antibody associated disease (MOGAD), longitudinally extensive myelitis (LETM), and acute disseminated encephalomyelitis (ADEM). Disability rates may be high despite treatment. Compared to Rituximab, cyclophosphamide has a faster onset of action, lower cost and is accessible in most hospitals. Experience in non-MS CNS inflammation is limited. Aim To review refractory non-MS CNS inflammation cases referred to the national NMOSD service treated with cyclophosphamide. Methods Patients with non-MS CNS inflammation refractory to standard relapse treatment administered cyclophosphamide were included from January 2018-2023. Clinical data including EDSS was collected. Results Ten patients were identified (AQP4-IgG-NMOSD=2, seronegative NMOSD=2, MOGAD=2, LETM=3, and ADEM=1). Of 7 patients with transverse myelitis, 6 had LETM. Median treatment age was 50(18-76) years and 70% were female. Prior immunosuppressive treatments were given; IV methylprednisolone (IVMP)=1, PLEX=1, IVMP/PLEX=5, IVMP/IVIg=1, IVMP/IVIg/PLEX=2. Median pre- and 3-month EDSS was 8(6.5-9) and 6.5(6-8.5). Adverse events including mild infection were recorded in 6 patients but resolved with appropriate treatment Conclusion Cyclophosphamide is an effective option for the treatment of refractory non-MS CNS inflam- mation. Adverse events were not uncommon but were effectively managed with no long-term sequelae. Ambulatory capacity was restored in most patients.

  • Do we still need OCBs in MS diagnosis and how many?

    by Mirasol Forcadela, Katherine Birch, Chiara Rocchi, Giovanna Campagna, Edward Jackson, Carrie Chadwick, Shahd Hamid, Anu Jacob, Saif Huda